New flu vaccine trial aims for stronger, Longer-Lasting protection

This early-stage study tests a new flu vaccine (STEMos1) in 56 healthy adults aged 18-50. Half of the participants get the vaccine with an adjuvant (a substance that boosts the immune response), and half get it without. The goal is to check safety and how well the vaccine triggers the body's defenses against flu. Participants receive two shots, four months apart, and are followed for 15 months.